阿托伐他汀,临床注释-2,变异和临床注释数据

id	等位基因	注释文本
1201	*15	The SLCO1B115 allele (defined as consisting of both rs4149056 and rs2306283) is assigned as a no function allele by CPIC. Patients carrying SLCO1B115 allele in combination with a normal, no, or increased function allele may have a higher risk of atorvastatin-related myopathy when treated with atorvastatin as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the toxicity of atorvastatin.
1200	*5	The SLCO1B15 allele (defined as consisting of rs4149056) is assigned as a no function allele by CPIC. Patients carrying SLCO1B15 allele in combination with a normal, no, or increased function allele may have a higher risk of atorvastatin-related myopathy when treated with atorvastatin as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the toxicity of atorvastatin.
1199	*1	The SLCO1B11 allele is assigned as a normal function allele by CPIC. Patients carrying SLCO1B11 allele in combination with another normal function allele may have a lower risk of atorvastatin-related myopathy when treated with atorvastatin as compared to patients with a no function allele in combination with a normal or increased function allele or with two no function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the toxicity of atorvastatin.

等位基因

注释文本

The SLCO1B1*15 allele (defined as consisting of both rs4149056 and rs2306283) is assigned as a no function allele by CPIC. Patients carrying SLCO1B1*15 allele in combination with a normal, no, or increased function allele may have a higher risk of atorvastatin-related myopathy when treated with atorvastatin as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the toxicity of atorvastatin.

1200

The SLCO1B1*5 allele (defined as consisting of rs4149056) is assigned as a no function allele by CPIC. Patients carrying SLCO1B1*5 allele in combination with a normal, no, or increased function allele may have a higher risk of atorvastatin-related myopathy when treated with atorvastatin as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the toxicity of atorvastatin.

1199

The SLCO1B1*1 allele is assigned as a normal function allele by CPIC. Patients carrying SLCO1B1*1 allele in combination with another normal function allele may have a lower risk of atorvastatin-related myopathy when treated with atorvastatin as compared to patients with a no function allele in combination with a normal or increased function allele or with two no function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the toxicity of atorvastatin.

id	证据的ID	总结
4154	1184989268	SLCO1B1 5 is associated with increased risk of Drug Toxicity when treated with atorvastatin, pravastatin or simvastatin in people with Hypercholesterolemia as compared to SLCO1B1 1.
4153	1449576945	Genotypes CC + CT are associated with increased likelihood of statin-related myopathy when treated with atorvastatin or simvastatin as compared to genotype TT.
4152	1448613086	Allele C is not associated with increased risk of Muscular Diseases when treated with atorvastatin, fluvastatin, hmg coa reductase inhibitors, pitavastatin, pravastatin, rosuvastatin or simvastatin as compared to allele T.
4151	1447689782	Genotypes CC + CT is associated with increased likelihood of Drug Toxicity, Muscular Diseases, Rhabdomyolysis and Toxic liver disease when treated with atorvastatin as compared to genotype TT.
4150	1183699594	Genotypes CC + CT are associated with increased risk of dose decrease or switch to another cholesterol-lowering drug in users with a starting dose of more than 20 mg when treated with atorvastatin as compared to genotype TT.
4149	1183689645	Allele C is associated with all statin-induced myopathy and severe myopathy when treated with atorvastatin, fluvastatin, hmg coa reductase inhibitors, pravastatin, rosuvastatin or simvastatin as compared to allele T.
4148	769164520	Allele C is not associated with risk of Muscular Diseases when treated with atorvastatin in people with Hyperlipidemias as compared to allele T.
4147	827810986	Genotypes CC + CT are not associated with increased risk of Myalgia unspecified when treated with atorvastatin in people with Hypercholesterolemia as compared to genotype TT.
4146	1451352267	Allele C is not associated with increased risk of statin-related myopathy when treated with atorvastatin or simvastatin in people with Dyslipidaemia as compared to allele T.
4145	1451480162	Genotypes CC + CT are not associated with increased risk of statin-related myopathy when treated with atorvastatin as compared to genotype TT.
4144	1451479880	Genotypes CC + CT are associated with increased risk of statin-related myopathy when treated with atorvastatin as compared to genotype TT.
4143	1451465304	Genotype CC is not associated with increased risk of statin-related myopathy when treated with atorvastatin as compared to genotype TT.
4142	1451390640	Genotypes CC + CT are not associated with increased risk of drug-induced liver injury when treated with atorvastatin as compared to genotype TT.
4141	1451390500	Genotypes CC + CT are associated with increased risk of statin-related myopathy when treated with atorvastatin as compared to genotype TT.
4140	1451390498	Genotypes CC + CT are not associated with increased risk of statin-related myopathy when treated with atorvastatin as compared to genotype TT.
4139	1448821136	Allele C is not associated with likelihood of statin-related myopathy when treated with atorvastatin or simvastatin in people with Coronary Artery Disease as compared to allele T.
4138	1451226140	Genotype TT is not associated with increased likelihood of Muscular Diseases when treated with atorvastatin or rosuvastatin in people with Diabetes Mellitus, Hyperlipidemias, Hypertension or Obesity as compared to genotypes CC + CT.
4137	1451163185	Allele C is associated with increased risk of Muscular Diseases when treated with atorvastatin.
4136	1451151642	Allele C is not associated with risk of statin-related myopathy due to atorvastatin as compared to allele T.
4135	PA166262221	Annotation of CPIC Guideline for atorvastatin and SLCO1B1

证据的ID

总结

4154

1184989268

SLCO1B1 *5 is associated with increased risk of Drug Toxicity when treated with atorvastatin, pravastatin or simvastatin in people with Hypercholesterolemia as compared to SLCO1B1 *1.

4153

1449576945

Genotypes CC + CT are associated with increased likelihood of statin-related myopathy when treated with atorvastatin or simvastatin as compared to genotype TT.

4152

1448613086

Allele C is not associated with increased risk of Muscular Diseases when treated with atorvastatin, fluvastatin, hmg coa reductase inhibitors, pitavastatin, pravastatin, rosuvastatin or simvastatin as compared to allele T.

4151